FLT3 and neoplasm: The combination of venetoclax and quizartinib, a small molecular oral FLT3-tyrosine kinase inhibitor (TKI), induced tumor regression in FLT3-mutant AML cell lines that was more durable than with either agent alone, preventing tumor re‐emergence for up to 3 months following cessation of therapy (54).